filmov
tv
Dave Ricks, CEO of Eli Lilly | The All-In Interview

Показать описание
(0:00) Friedberg welcomes Eli Lilly CEO Dave Ricks
(2:06) The obesity problem: a global chronic health epidemic
(13:07) The history of discovering GLP-1s
(20:38) Impact of GLP-1s on different human functions
(27:09) Understanding the commercial aspect of drug discovery, pricing for GLP-1 drugs
(33:11) Responding to criticism and research of GLP-1 dependency
(40:04) Stock performance, dealing with political pressure related to successful drugs
(47:19) Eli Lilly's portfolio of drugs outside of GLP-1s, what science Dave is excited about
(56:09) Scaling and impacting culture at a 100+ year-old company
Follow the besties:
Follow on X:
Follow on Instagram:
Follow on TikTok:
Follow on LinkedIn:
Intro Music Credit:
Intro Video Credit:
Referenced in the show:
#allin #tech #news
(2:06) The obesity problem: a global chronic health epidemic
(13:07) The history of discovering GLP-1s
(20:38) Impact of GLP-1s on different human functions
(27:09) Understanding the commercial aspect of drug discovery, pricing for GLP-1 drugs
(33:11) Responding to criticism and research of GLP-1 dependency
(40:04) Stock performance, dealing with political pressure related to successful drugs
(47:19) Eli Lilly's portfolio of drugs outside of GLP-1s, what science Dave is excited about
(56:09) Scaling and impacting culture at a 100+ year-old company
Follow the besties:
Follow on X:
Follow on Instagram:
Follow on TikTok:
Follow on LinkedIn:
Intro Music Credit:
Intro Video Credit:
Referenced in the show:
#allin #tech #news
Dave Ricks, CEO of Eli Lilly | The All-In Interview
The David Rubenstein Show: Eli Lilly CEO Dave Ricks
Exclusive | Eli Lilly CEO Dave Ricks On New Weight Loss Drug 'Mounjaro' | Global Dialogues
Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicine
David Ricks - CEO of Eli Lilly | Podcast | In Good Company | Norges Bank Investment Management
Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing
Eli Lilly CEO David Ricks on Q1 results, weight loss drug competition and status of weight-loss pill
Eli Lilly CEO David Ricks: Projecting 32% total growth for company in 2025
Eli Lilly CEO David Ricks on 3-year obesity drug study: This is a profound result
Footprints: Dave Ricks
Eli Lilly CEO David Ricks on pricing of the new weight loss pill if approved
Eli Lilly Is Working on an Anti-Obesity Pill, Says CEO Dave Ricks
Eli Lilly CEO on $27 billion investment in U.S. manufacturing expansion
Eli Lilly CEO on slashing insulin prices, approval timelines for weight-loss and Alzheimer's dr...
A Breakthrough in Health: How GLP-1s Are Redefining Pharma with David Ricks and Fatima Cody Stanford
Eli Lilly CEO David Ricks breaks down second-quarter earnings and drug pipeline
American big pharma boss doesn’t support tariffs on Australian medicines | 7.30
Eil Lilly announces Zepbound to be sold directly to consumers
Eli Lilly CEO David Ricks on GLP-1 and obesity drugs
Eli Lilly’s CEO David Ricks delves into the drivers of the healthcare industry
Eli Lilly CEO David Ricks on Q3 results: The underlying growth story is fantastic
Distinguished Purdue Alumni | Meet Dave Ricks: CEO of Eli Lilly
Eli Lilly CEO on Fighting Obesity, Developing New Drugs
Eli Lilly CEO on weight loss drugs outlook: Our top priority is making more product
Комментарии